Surya Prabha Sadhu

Surya Prabha Sadhu

Auto-generated profile, based on publicly available information

Surya Prabha Sadhu

AU College of Pharmaceutical Sciences, Department of Pharmacology, Andhra University, Visakhapatnam – 530003, Andhra Pradesh, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Narasimha BeerakaNarasimha Beeraka
Narasimha Beeraka
SNs n
s n
SSSurya P. Sadhu
Surya P. Sadhu
ASAsha Srinivasan
Asha Srinivasan
RPRajeswara Rao Pragada
Rajeswara Rao Pragada
Gjumrakch AlievGjumrakch Aliev
Gjumrakch Aliev
Exosomes exhibit a wide range of biological properties and functions in the living organisms. They are nanometric vehicles and used for delivering drugs, as they are biocompatible and minimally immunogenic. Exosomal secretions derived from cancer cells contribute to metastasis, immortality, angiogenesis, tissue invasion, stemness and chemo/radio-resistance. Exosome-derived microRNAs (miRNAs) and long non-coding RNAs (lnc RNAs) are involved in the pathophysiology of cancers and neurodegenerative diseases. For instance, exosomes derived from mesenchymal stromal cells, astrocytes, macrophages, and acute myeloid leukemia (AML) cells are involved in the cancer progression and stemness as they induce chemotherapeutic drug resistance in several cancer cells. This review covered the recent research advances in understanding the role of exosomes in cancer progression, metastasis, angiogenesis, stemness and drug resistance by illustrating the modulatory effects of exosomal cargo (ex. miRNA, lncRNAs, etc.) on cell signaling pathways involved in cancer progression and cancer stem cell growth and development. Recent reports have implicated exosomes even in the treatment of several cancers. For instance, exosomes-loaded with novel anti-cancer drugs such as phytochemicals, tumor-targeting proteins, anticancer peptides, nucleic acids are known to interfere with drug resistance pathways in several cancer cell lines. In addition, this review depicted the need to develop exosome-based novel diagnostic biomarkers for early detection of cancers and neurodegenerative disease. Furthermore, the role of exosomes in stroke and oxidative stress-mediated neurodegenerative diseases including Alzheimer’s disease (AD), and Parkinson’s disease (PD) is also discussed in this article.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Narasimha BeerakaNarasimha Beeraka
Narasimha Beeraka
TULIMILLI VENKATA SUBBA RAOTULIMILLI VENKATA SUBBA RAO
TULIMILLI VENKATA SUBBA RAO
MKMedha Karnik
Medha Karnik
SSSurya P. Sadhu
Surya P. Sadhu
RPRajeswara Rao Pragada
Rajeswara Rao Pragada
SubbaRao V. MadhunapantulaSubbaRao V. Madhunapantula
SubbaRao V. Madhunapantula
Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) infection causes coronavirus disease‐19 (COVID‐19), which is characterized by clinical manifestations such as pneumonia, lymphopenia, severe acute respiratory distress, and cytokine storm. S glycoprotein of SARS‐CoV‐2 binds to angiotensin‐converting enzyme II (ACE‐II) to enter into the lungs through membrane proteases consequently inflicting the extensive viral load through rapid replication mechanisms. Despite several research efforts, challenges in COVID‐19 management still persist at various levels that include (a) availability of a low cost and rapid self‐screening test, (b) lack of an effective vaccine which works against multiple variants of SARS‐CoV‐2, and (c) lack of a potent drug that can reduce the complications of COVID‐19. The development of vaccines against SARS‐CoV‐2 is a complicated process due to the emergence of mutant variants with greater virulence and their ability to invoke intricate lung pathophysiology. Moreover, the lack of a thorough understanding about the virus transmission mechanisms and complete pathogenesis of SARS‐CoV‐2 is making it hard for medical scientists to develop a better strategy to prevent the spread of the virus and design a clinically viable vaccine to protect individuals from being infected. A recent report has tested the hypothesis of T cell immunity and found effective when compared to the antibody response in agammaglobulinemic patients. Understanding SARS‐CoV‐2‐induced changes such as “Th‐2 immunopathological variations, mononuclear cell & eosinophil infiltration of the lung and antibody‐dependent enhancement (ADE)” in COVID‐19 patients provides key insights to develop potential therapeutic interventions for immediate clinical management. Therefore, in this review, we have described the details of rapid detection methods of SARS‐CoV‐2 using molecular and serological tests and addressed different therapeutic modalities used for the treatment of COVID‐19 patients. In addition, the current challenges against the development of vaccines for SARS‐CoV‐2 are also briefly described in this article.

28 February 2023 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
SSSurya Prabha Sadhu
Surya Prabha Sadhu
RPRajeswara Rao Pragada
Rajeswara Rao Pragada
PKPrasad Konduri
Prasad Konduri
NYNagendra Sastry Yarla
Nagendra Sastry Yarla
Objectives: The present study reports antioxidant potential, the in-vitro antiproliferative activity of saccharumoside-B, and molecular docking studies on the binding affinity of saccharumoside-B towards various proteins involved in breast cancer pathogenesis. Methods: The in-vitro antioxidant activity of saccharumoside-B was determined by DPPH, superoxide and nitric oxide free radical scavenging assays. The antiproliferative activity was evaluated in-vitro by MTT assay. The binding affinity of saccharumoside-B towards the HSP90, HER2, human estrogen receptor and tyrosine-protein kinase C-SRC were determined by the molecular docking studies. Results: Saccharumoside-B showed a significant dose-dependent antioxidant activity and potent dose-dependent antiproliferative effect on the MCF-7 breast cancer cell line (IC50 = 22.57±0.39µM) among all other cell lines studied. Tamoxifen was used as a positive control for MCF-7 cell line (IC50 = 27.97±1.07µM). The IC50 of saccharumoside-B on normal MCF-10A cell line (IC50>1000µM) showed a promising safety profile, whereas tamoxifen’s IC50 on MCF-10A normal cell line was found to be 29.6 ± 0.84 µM. The molecular docking analysis revealed that saccharumoside-B was inserted into the active site pockets of all the tested proteins involved in the breast cancer pathogenesis with varying binding affinities. Conclusion: The antioxidant studies revealed the potential antioxidant effect of saccharumoside-B. The in-vitro and in-silico studies are indicating the safe and multiple target protein inhibitory potential of saccharumoside-B against breast cancer. This study suggests that saccharumoside-B can be developed into a new class of anticancer drugs with a high safety profile in the future.

1 June 2021 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SSSurya Prabha Sadhu
Surya Prabha Sadhu
NYNagendra Sastry Yarla
Nagendra Sastry Yarla
RPRajeswara Rao Pragada
Rajeswara Rao Pragada
PKPrasad Konduri
Prasad Konduri
Background: Saccharumoside-B and its analogs were found to have anticancer potential in vitro. The present study reports acute toxicity, molecular docking, ADMET profile analysis, and in vitro and in vivo anti-inflammatory activity of saccharumoside-B for the first time. Methods: The in vitro enzyme inhibitory activity of saccharumoside-B on PLA2, COX-1, COX-2, and 5-LOX enzymes was evaluated by the cell-free method, and its effect on TNF-α, IL1β, and IL- 6 secretion levels in LPS stimulated THP-1 human monocytes was determined by ELISA-based methods. The anti-inflammatory activity was evaluated in vivo by carrageenan-induced rat paw edema model. To test its binding affinity at the active site pockets of PLA2 enzymes and assess drug-like properties, docking experiments and ADMET studies were performed. Results: Saccharumoside-B showed selective inhibition of the sPLA2 enzyme (IC50 = 7.53 ± 0.232 μM), and thioetheramide-PC was used as a positive control. It showed significant inhibition (P ≤ 0.05) of TNF-α, IL-1β, and IL-6 cytokines compared to the positive control dexamethasone. Saccharumoside-B showed a dose-dependent inhibition of carrageenan-induced rat paw edema, with a maximum inhibition (76.09 ± 0.75) observed at 3 hours after the phlogistic agent injection. Saccharumoside-B potentially binds to the active site pocket of sPLA2 crystal protein (binding energy -7.6 Kcal/Mol). It complies with Lipinski’s Rule of Five, showing a promising safety profile. The bioactivity scores suggested it to be a better enzyme inhibitor. Conclusion: Saccharumoside-B showed significant PLA2 inhibition. It can become a potential lead molecule in synthesizing a new class of selective PLA2 inhibitors with a high safety profile in the future.